Protherics expanded its core franchise through the transfer of the market rights for Digitalis Antidot® from Roche. Protherics intends to replace Roche’s Digitalis Antidot in the market with its own DigiFab, a sheep-derived Fab preparation licensed in US for treating digoxin toxicity/overdose.